Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 35Leukemia 30Precursor Cell Lymphoblastic Leukemia-Lymphoma 27Lymphoma 27Lymphoma, Non-Hodgkin 22Burkitt Lymphoma 21Lymphoma, Mantle-Cell 20Leukemia, Lymphocytic, Chronic, B-Cell 20Lymphoma, Large B-Cell, Diffuse 19Lymphoma, Follicular 19Neuroblastoma 18Myelodysplastic Syndromes 18Multiple Myeloma 18Lymphoma, Large-Cell, Immunoblastic 17Lymphoma, B-Cell, Marginal Zone 17Hodgkin Disease 15Astrocytoma 14Medulloblastoma 13Breast Neoplasms 13Recurrence 12Central Nervous System Neoplasms 12Sarcoma 11Myeloproliferative Disorders 10Leukemia, Myeloid, Chronic-Phase 10Ovarian Neoplasms 9Leukemia, Myeloid, Accelerated Phase 9Familial ependymoma 9Carcinoma, Ovarian Epithelial 9Blast Crisis 9Optic Nerve Glioma 8

Interventions

Bortezomib 3filanesib 2Tacrolimus 2Peripheral Blood Stem Cell Transplantation 2Melphalan 2Lenalidomide 2Dexamethasone 2sargramostim 1montanide ISA 51 1merphos 1liposomal doxorubicin 1ixazomib 1itacitinib 1incomplete Freund's adjuvant 1fludarabine phosphate 1dexamethasone acetate 1dexamethasone 21-phosphate 1daratumumab 1carfilzomib 1auricularum 1Steroids 1Stem Cell Transplantation 1Sirolimus 1Proteasome Inhibitors 1Methotrexate 1Injections, Subcutaneous 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Etoposide 1Doxorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Leukemia, Plasma Cell × Filgrastim × Clear all
NCT01248923 2020-09-30

A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

Array BioPharma

Phase 1 Completed
55 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma, Paraproteinemias, Plasmacytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡